H
Hongming Pan
Researcher at Sir Run Run Shaw Hospital
Publications - 172
Citations - 10374
Hongming Pan is an academic researcher from Sir Run Run Shaw Hospital. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 28, co-authored 122 publications receiving 7818 citations. Previous affiliations of Hongming Pan include Zhejiang University.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Ann-Lii Cheng,Yoon-Koo Kang,Zhendong Chen,Chao Jung Tsao,Shukui Qin,Jun Suk Kim,Rongcheng Luo,Jifeng Feng,Sheng-Long Ye,Tsai Sheng Yang,Jianming Xu,Yan Sun,Houjie Liang,Jiwei Liu,Jiejun Wang,Won Young Tak,Hongming Pan,Karin Burock,Jessie Zou,D. Voliotis,Zhongzhen Guan +20 more
TL;DR: Sorafenib is effective for the treatment of advanced hepatocellular carcinoma in patients from the Asia-Pacific region, and is well tolerated.
Journal ArticleDOI
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
Jin Li,Shukui Qin,Rui-Hua Xu,Thomas Yau,Brigette B.Y. Ma,Hongming Pan,Jianming Xu,Yuxian Bai,Yihebali Chi,Liwei Wang,Kun-Huei Yeh,F. Bi,Ying Cheng,Anh Tuan Le,Jen Kou Lin,Tianshu Liu,Dong Ma,Christian Kappeler,Joachim Kalmus,Tae Won Kim +19 more
TL;DR: This phase 3 trial is the second to show an overall survival benefit with regorafenib compared with placebo in patients with treatment-refractory metastatic metastatic colorectal cancer, substantiating the role of regorAFenib.
Journal ArticleDOI
Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
Calin Cainap,Shukui Qin,Wen-Tsung Huang,Ik Joo Chung,Hongming Pan,Ying Cheng,Masatoshi Kudo,Yoon-Koo Kang,Pei-Jer Chen,Han Chong Toh,Vera Gorbunova,Ferry A.L.M. Eskens,Jiang Qian,Mark D. McKee,Justin L. Ricker,Dawn M. Carlson,Saied El-Nowiem +16 more
TL;DR: Linifanib and sorafenib had similar OS in advanced HCC and the study failed to meet the primary end point, despite defined superiority and noninferiority OS boundaries being met.
Journal ArticleDOI
BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer
Caicun Zhou,Yi-Long Wu,Gongyan Chen,Xiaoqing Liu,Yunzhong Zhu,Shun Lu,Jifeng Feng,Jianxing He,Baohui Han,Jie Wang,Guo-Liang Jiang,Chunhong Hu,Hao Zhang,Gang Cheng,Xiangqun Song,You Lu,Hongming Pan,Wenjuan Zheng,Anny-Yue Yin +18 more
TL;DR: The addition to bevacizumab to carboplatin/paclitaxel was well tolerated and resulted in a clinically meaningful treatment benefit in Chinese patients with advanced nonsquamous NSCLC.
Journal ArticleDOI
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial
Yi-Long Wu,Jin Soo Lee,Sumitra Thongprasert,Chong-Jen Yu,Li Zhang,Guia Ladrera,Vichien Srimuninnimit,Virote Sriuranpong,Jennifer Sandoval-Tan,Yunzhong Zhu,Meilin Liao,Caicun Zhou,Hongming Pan,V. Lee,Yuh Min Chen,Yuh Min Chen,Yan Sun,Benjamin Margono,Fatima Fuerte,Gee-Chen Chang,Kasan Seetalarom,Jie Wang,Ashley Cheng,Elisna Syahruddin,Xiaoping Qian,James Chung-Man Ho,Johan Kurnianda,Hsingjin Eugene Liu,Kate Jin,Matt Truman,Ilze Bara,Tony Mok +31 more
TL;DR: Intercalated chemotherapy and erlotinib is a viable first-line option for patients with non-small-cell lung cancer with EGFR mutation-positive disease or selected patients with unknown EGFR mutations status.